---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-076482"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:22:38.391222+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aptevo receives Nasdaq delisting notice for equity deficiency; announces 1-for-20 reverse split

## Summary
- Nasdaq notified Aptevo of non-compliance with $2.5M stockholders' equity rule; deficit of $1.473M as of March 31, 2025.
- Company has 45 days (by July 7, 2025) to submit compliance plan; if accepted, until Nov 18, 2025 to regain compliance.
- Announces 1-for-20 reverse stock split effective May 23, 2025; shares begin trading split-adjusted May 27.
- Files prospectus supplement for up to $3.015M of common stock under ATM with Roth Capital.
- Outstanding shares to reduce from ~13.5M to ~0.7M; no change to ticker APVO.

## SEC filing metadata
- accession: 0000950170-25-076482
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017025076482/0000950170-25-076482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017025076482/apvo-20250522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-076482
- JSON: https://secwatch.observer/filing/0000950170-25-076482.json
- Plain text: https://secwatch.observer/filing/0000950170-25-076482.txt

## Key facts
- Listing & Compliance Notices
  Aptevo Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 22, 2025, Aptevo Therapeutics Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its Quarterly Report for the quarterly period ended March 31, 2025, the Company reported stockholders’ deficit of $1,473,000, and, as a result, does not currently satisfy Nasdaq Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing o
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017025076482/0000950170-25-076482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.